Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria (Aerius)

Organon

Status: Completed

Conditions: Rhinitis; Urticaria

Treatments: Drug: Desloratadine

Study type: Observational

Funder types: Industry

Identifiers

NCT00724698

P04706

Details and patient eligibility

About

Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.

Enrollment: 3,011 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Outpatient men or women, age 12 years and above.
• Diagnosis of Allergic Rhinitis or Chronic Idiopathic Urticaria

Exclusion criteria

• Known hypersensitivity to Desloratadine.
• Pregnancy or lactation

Trial design

3,011 participants in 1 patient group

Group

Description:

Patients diagnosed with Allergic Rhinitis or Chronic Idiopathic Urticaria

Treatment:

Drug: Desloratadine